Langbahn Team – Weltmeisterschaft

Miglitol

Not to be confused with Meglutol.
Miglitol
Structural diagram of miglitol
Clinical data
Trade namesGlyset
AHFS/Drugs.comMonograph
MedlinePlusa601079
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityDose-dependent
Protein bindingNegligible (<4.0%)
MetabolismNil
Elimination half-life2 hours
ExcretionRenal (95%)
Identifiers
  • (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)
    piperidine-3,4,5-triol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.069.670 Edit this at Wikidata
Chemical and physical data
FormulaC8H17NO5
Molar mass207.226 g·mol−1
3D model (JSmol)
Density1.458 g/cm3
Melting point114 °C (237 °F)
  • OCCN1[C@@H]([C@@H](O)[C@H](O)[C@@H](O)C1)CO
  • InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1 checkY
  • Key:IBAQFPQHRJAVAV-ULAWRXDQSA-N checkY
  (verify)

Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes. It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels.[1] Approved for clinical use since 1998, miglitol has demonstrated efficacy in improving glycemic control, reducing HbA1c levels, and decreasing both fasting and postprandial plasma glucose concentrations in long-term clinical trials.[1][2] Additionally, recent studies have suggested that miglitol may have potential as an anti-obesity agent, showing promise in reducing body weight and body mass index in obese or diabetic patients.[3] While generally well-tolerated, the most common side effects associated with miglitol are gastrointestinal disturbances, which are typically mild to moderate and tend to decrease over time.[1]

It must be taken at the start of main meals to have maximal effect[4]

In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.

Formulation

The benefits of alpha-glucosidase inhibitors on health were shown to be stronger when the powder is consumed orally dissolved in water as a beverage in comparison to its intake as ordinary hard gelatin capsules.[5]

See also

References

  1. ^ a b c Scott LJ, Spencer CM (March 2000). "Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus". Drugs. 59 (3): 521–49. doi:10.2165/00003495-200059030-00012. PMID 10776834.
  2. ^ "Migliotl: MedlinePlus Drug Information". MedlinePlus. National Institutes of Health. 1 September 2010. Retrieved 13 April 2013.
  3. ^ Sugimoto S, Nakajima H, Kosaka K, Hosoi H (2015). "Review: Miglitol has potential as a therapeutic drug against obesity". Nutrition & Metabolism. 12: 51. doi:10.1186/s12986-015-0048-8. PMC 4666030. PMID 26628904.
  4. ^ "Glyset (miglitol) tablets label - Accessdata FDA" (PDF). Drugs@FDA. U.S. Food and Drug Administration. August 2012. Retrieved 13 April 2013.
  5. ^ Moreira FD, Reis CE, Gallassi AD, Moreira DC, Welker AF (2024-10-09). Dardari D (ed.). "Suppression of the postprandial hyperglycemia in patients with type 2 diabetes by a raw medicinal herb powder is weakened when consumed in ordinary hard gelatin capsules: A randomized crossover clinical trial". PLOS ONE. 19 (10): e0311501. Bibcode:2024PLoSO..1911501M. doi:10.1371/journal.pone.0311501. PMC 11463819. PMID 39383145. This article incorporates text from this source, which is available under the CC BY 4.0 license.


Quelle: http://en.wikipedia.org/wiki/Miglitol